The Omar Boraie Chair is Established at the Highly Regarded Rutgers Cancer Institute:

Pioneering research in the way of highly refined medicine at the Rutgers Cancer Institute of New Jersey: the Omar Boraie Chair, as it applies to Genomic Science, has been created. The preceding, undoubtedly, is a very prestigious standard in the way of purpose with respect to higher education–in the field of medicine.

Endowed chairs are expressive of the dedication of the educational institution in the form of the proper academic disciplines, and needless to mention, at the very highest of levels. The endowed chair is, in place, to assure that there is continual support and progress with regard to the research.

The chair is named in accord with Omar Boraie—the New Brunswick developer. The establishment of the Omar Boraie Chair is a part of the University’s ’18 New Chair Challenge’ campaign. The donor, who is anonymous, is providing one and one-half million dollars to match each of the eighteen new chairs, resulting, in way of an impressive three million dollar endowment:

An endowed chair or professorship is a position which is one that is permanently paid. The revenues come from that of the established endowment fund. The fund is set up precisely for the purpose of the chair. The position is generally designated alignment, with respect to a particular department, within the educational institution setting. The donor is allowed to indicate the post.

Genomic Science and that of highly-refined precision remedies is a field that evolves in many different directions: so it is in continual motion and changes—on a frequent basis. It involves the proper analyses and treatment of specific tumors, relying on a certain level of genetics. The research, then, makes it possible, for the Oncologist, to properly prescribe the correct individualized remedies—in order to achieve the highest success levels.

President Obama—during his tenure as President of the United States—announced the launch of the National Precision Medicine Initiative. The initiative’s primary focus was that of finding a cure for Cancer, as well as other Diseases.

It is true that many healthcare institutions, are devoted to performing, Next Generation Gene Sequencing, on tumors—in the way of research. However, the Rutgers Cancer Institute was, historically, one of the first centers, within the United States; and the only one in the State, that applies Genomic sequencing—in way of a form of precision medicine. The preceding activity was part of an approach in order to establish high levels of client care.

Genome sequencing is relative to determining the order of nucleotides; or bases in a genome. This encompasses the precise order of As, Cs, Gs, and Ts that are part of the organism’s DNA. The genome is comprised of well over three-billion of these genetic letters.

The goal, as it applies to genome research, is to catalyze communities, resources and tools; and procedures and policies, in order to provide research. The research, naturally, is to facilitate the proper sequencing of individual genomes. The information, then, is made use of in order to gain knowledge as to individualized risk profiles with regard to the Disease. Areas researched are inclusive of physical elements; certain biological characteristics as well as a person’s ancestry.

Genome sequencing is very useful in attainment of finding the best therapeutic formulas for those individuals suffering from rare disorders or disease. The preceding individuals, most generally, present with very unfavorable prognoses. Such individual cases, as to levels of treatment, can prove somewhat limiting—or worst case scenario—unsubstantial.

By advancing precision medicine there is a positive increase in way of the health institution’s staff, properly classifying certain forms of Cancers—into subpopulations—that have similar characteristics. The subpopulations may have nearly the same characteristics; however, are different from a genetic standpoint.

The preceding activities, naturally, make successful therapies more possible. The activities, too, are relative in determining the proper, individual therapies with regard to the disease.

The Scientists at the Rutgers Cancer Institute are well on their way of rendering a number of significant advances as it applies to patients, whose level of treatments are no longer responsive, in the form of precision medicine. The thought is to apply the same level of treatment to Cancer patients—across the board.

Mr. Boraie has a background in Chemistry. He has always found the field of Cancer Research, highly interesting.

Mr. Boraie, mentioned that, in like manner, as the anonymous donor for the ‘18 Chair Challenge’ came to the forefront; he is, as well, encouraging other individuals to come forward with a generous donation. It is Mr. Boraie’s greatest hope that the pledge, made by his family, will motivate other persons to do the same.

“Mr. Boraie, it goes without saying, is very much a part of the development happening within the New Brunswick area. The city is referenced to as the : ‘Healthcare City’. Mr. Boraie’s motivation is to provide proper support of the Endowed Chair in Genomic Science. The preceding endowed chair is certain to provide impact with respect to the field of Cancer research. The endowed chair will provide a lasting element of substantial hope for not only patients located in the New Brunswick area; but will have a reach that extends well beyond the city. The generous donation of the Endowed Chair is most appreciated,”—were the thoughts expressed by Robert S. DiPaola, MD. Dr. DiPaola is the Director of the Rutgers Cancer Institute.

Shridar Ganesan, MD, PhD, is the Associate Director for Translational Science and the Principal Investigator of the Precision Medicine Clinical Trial at the Rutgers Cancer Institute. Shridar Ganesan, M.D., PhD is also the Associate Professor of Medicine and Pharmacology at the Rutgers’ Robert Wood Johnson Medical School. Dr. Shridar Ganeson has been named Chair.

Dr. Shridar Ganesan is a Medical Oncologist. He is well-regarded on a global level. Dr. Ganesan is known as a leader as well as celebrated academic researcher. Dr. Ganesan joined the institution in 2005. He originally came from the Dana-Farber Cancer Institute at the Harvard Medical School.

Dr. Ganesan provided the following insights (not verbatim): Dr. Ganesan indicated that the knowledge that has been forthcoming, over the years, is that Cancer is not a singular Disease. Cancer is, rather, a collection of diseases. Each of the diseases have distinctive characteristics. Time-saving genomic analyses opens new doors in order to provide additional classifications. The added classifications are provided by way of a set of changes which are present in each form of cancer. These changes are useful, as a guide, in determining precise and customized forms of therapy.

He further added that he was honored to be named the Omar Boraie Chair in Genomic Science. He conveyed that the pledge will make possible innovations in way of Clinical Research. Such research makes it possible for the scientist-physician to gain new forms of understanding as it applies to Cancer Biology. In the end, the research serves to greatly benefit the Cancer patient. With these insights, there is a sense of renewed hopefulness for the families of Cancer patients as well as the patient.

Rutgers Cancer Institute of New Jersey is the state’s first and foremost National Cancer Institute. It is designated as a comprehensive Cancer Center. The Cancer Institute of New Jersey is very committed to the improvement of properly detecting and treating Cancer, with regard to the healthcare patient, it so dedicate serves. It wishes to place itself, within the healthcare community, as a viable resource, with regard to educating the public; and in the prevention of the disease.

The Physicians-Scientists, at the Institute, conduct activities in translational research. The Physician-Scientist takes what he has learned, within the laboratory setting, and applies it to his clinical practice. The preceding brings life to the research, itself.

The Cancer Institute of New Jersey is a network which is comprised of hospitals throughout the state. The centers provide the highest level of healthcare as it applies to the disease. The main hospital, within the network, is the Robert Wood Johnson University Hospital. The system’s partner is Meridian Health. The network is comprised, too, of many affiliate hospitals.

Notes Regarding Omar Boraie and Boraie Development LLC:

Omar Borarie is one of the visionaries that has breathed life back into the New Brunswick area. His success, in the way of real estate development, is unparalleled. However, Sam Boraie remains humble as well as appreciative to all of the contributors, with respect to the re-invention of the New Brunswick area. He makes special mention of the following companies and individuals, in bringing, New Brunswick, back to life–and making it the thriving metropolis it has become today. These special contributors include:

1—Dick Sellers—the President of Johnson & Johnson. (Omar Boraie states, in so many words, that Sellers is greatly responsible, with regard to the renaissance that occurred, within the New Brunswick area. He further stated that if Johnson & Johnson had not decided to stay in the area; nothing would have occurred.)

2—Other individuals included in the reinvention of the New Brunswick area are: John Lynch, John Heldrich, (Mayor) James Cahill, Harvey Holzberg, and David Crabiel.

3—Entities that contributed much to the renaissance of the city were: New Brunswick Tomorrow; the New Brunswick Development Corporation and Rutgers University.

Boraie Development, LLC is a real estate company. According to NJ Biz, the Boraie Development LLC is a real estate development, property management and sales and marketing organization. The company works in cooperation with financial institutions, architects and contractors in the completion of real estate projects.

The preceding news article was originally published by way of:

Other resources:

To read more about Boraie Development, visit